Surgical Oncology
Volume 14, Issue 4 , Pages 179-193 , December 2005

Yttrium-90 internal radiation therapy for hepatic malignancy

  • Sean Garrean

      Affiliations

    • Department of Surgery, The University of Illinois at Chicago, 840 S. Wood St. MC 958, Chicago, IL 60612, USA
    • ,
  • N. Joseph Espat

      Affiliations

    • Department of Surgery, Hepatobiliary and Oncologic Surgery, The University of Illinois at Chicago, 840 S. Wood St. MC 958, Chicago, IL 60612, USA
    • Corresponding Author InformationCorresponding author. Tel.: +13123551493; fax: +13123551987.

References 

  1. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al. Improvement in peri-operative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Annals of Surgery. 2002;236(4):397–407
  2. Cha C, DeMatteo RP, Blumgart LH. Surgery and ablative therapy for hepatocellular carcinoma. Journal of Clinical Gastroenterology. 2002;35(5, Suppl 2):S130–S137
  3. D’Angelica M, Fong Y. The liver. In:  Townsend C,  Beauchamp RD,  Evers BM,  Mattox KL editor. Sabiston textbook of surgery: the biological basis of modern surgical practice. Philadelphia: Elsevier Saunders; 2004;p. 1513–1573
  4. Fong Y, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a western center. Annals of Surgery. 1999;229(6):790–800
  5. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine. 1996;334(11):693–699
  6. Lau WY, Leung TW, Yu SC, Ho SK. Percutaneous local ablative therapy for hepatocellular carcinoma. Annals of Surgery. 2003;237(2):171–179
  7. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Annals of Surgery. 2002;235(4):466–486
  8. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Annals of Surgery. 1999;229(2):216–222
  9. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Annals of Surgery. 1997;226(6):688–703
  10. Troisi R, Defreyne L, Hesse UJ, Praet M, Decruyenaere J, De Hemptinne B. Multimodality treatment for hepatocellular carcinoma on cirrhosis: the role of chemoembolization and alcoholization before liver transplantation. Clinical Transplantation. 1998;12(4):313–319
  11. Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The natural history of hepatic metastases from colorectal cancer: a comparison with resective treatment. Annals of Surgery. 1984;199(5):502–508
  12. Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al. Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Annals of Surgery. 1999;230(1):1–8
  13. Heisterkamp J, van Hillegersberg R, Ijzermans JN. Interstitial laser coagulation for hepatic tumours. British Journal of Surgery. 1999;86(3):293–304
  14. Bismuth H, Adam R, Levi F, Farabos C, Waechter F, Castaing D, et al. Resection of non-resectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Annals of Surgery. 1996;224(4):509–522
  15. Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Annals of Surgery. 2004;240(2):299–305
  16. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transplantation. 2004;10(2, Suppl 1):S107–S110
  17. Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. Journal of Vascular and Interventional Radiology. 2004;15(4):335–345
  18. Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. International Journal of Radiation Oncology Biology Physics. 1995;31(5):1237–1248
  19. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. International Journal of Radiation Oncology Biology Physics. 2004;60(5):1552–1563
  20. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(Suppl 1):S41–S55
  21. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. Journal of Surgical Oncology. 2004;88(2):78–85
  22. Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90Yttrium-microspheres for inoperable hepatic tumors. International Journal of Radiation Oncology Biology Physics. 1995;33(4):919–924
  23. Ariel IM. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Annals of Surgery. 1965;162:267–278
  24. Shepherd FA, Rotstein LE, Houle S, Yip TC, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer. 1992;70(9):2250–2254
  25. Houle S, Yip TK, Shepherd FA, Rotstein LE, Sniderman KW, Theis E, et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology. 1989;172(3):857–860
  26. Mantravadi RV, Spigos DG, Tan WS, Felix EL. Intraarterial yttrium 90 in the treatment of hepatic malignancy. Radiology. 1982;142(3):783–786
  27. Dancey JE, Shepherd FA, Paul K, Sniderman KW, Houle S, Gabrys J, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. Journal of Nuclear Medicine. 2000;41(10):1673–1681
  28. Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(5, Suppl 1):S194–S205
  29. Liu M, Uaje M, Al-ghazi MS, Fields D, Herman J, Kuo JV, et al. Use of yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. American Surgeon. 2004;70(11):947–953
  30. Yan ZP, Lin G, Zhao HY, Dong YH. An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer. 1993;72(11):3210–3215
  31. Cao X, He N, Sun J, Tan J, Zhang C, Yang J, et al Hepatic radioembolization with Yttrium-90 glass microspheres for treatment of primary liver cancer. Chinese Medical Journal. 1999;112(5):430–432
  32. Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. British Journal of Cancer. 1994;70(5):994–999
  33. Lau WY, Ho S, Leung TW, Chan M, Ho R, Johnson PJ, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. International Journal of Radiation Oncology Biology Physics. 1998;40(3):583–592
  34. Lau WY, Ho S, Leung WT, Chan M, Lee WY, Johnson PJ. What determines survival duration in hepatocellular carcinoma treated with intraarterial yttrium-90 microspheres?. Hepatogastroenterology. 2001;48(38):338–340
  35. Stubbs R, Cannan RJ, Mitchell A. Selective internal radiation therapy with 90 Yttrium microspheres for extensive colorectal liver metastases. Journal of Gastrointestinal Surgery. 2001;5(3):294–302
  36. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepatogastroenterology. 2001;48(38):333–337
  37. Stubbs RS, Wickremesekera SK, Boppudi S. Selective internal radiation therapy (SIRT) for the treatment of advanced colorectal liver metastases. Journal of Gastrointestinal Surgery. 2003;7:262–263
  38. Gray BN, Burton MA, Kelleher DK, Anderson J, Klemp P. Selective internal radiation (SIR) therapy for treatment of liver metastases: measurement of response rate. Journal of Surgical Oncology. 1989;42(3):192–196
  39. Gray BN, Anderson JE, Burton MA, van Hazel G, Codde J, Morgan C, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Australian and New Zealand Journal of Surgery. 1992;62(2):105–110
  40. Gray BN, Van Hazel G, Buck M, Paton G, Burton M, Anderson J. Treatment of colorectal liver metastases with SIR-Spheres plus chemotherapy. Gastrointestinal Cancer. 2000;3(4):249–257
  41. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Annals of Oncology. 2001;12(12):1711–1720
  42. Murthy R, Xiong H, Nunez R, Cohen AC, Barron B, Szklaruk J, et al. Yttrium 90 resin microspheres for the treatment of unresectable colorectal hepatic metastases after failure of multiple chemotherapy regimens: preliminary results. Journal of Vascular and Interventional Radiology. 2005;16(7):937–945
  43. Popperl G, Helmberger T, Munzing W, Schmid R, Jacobs TF, Tatsch K. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. Cancer Biotherapy Radiopharmcy. 2005;20(2):200–208
  44. Lim L, Gibbs P, Yip D, Shapiro JD, Dowling R, Smith D, et al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Internal Medicine Journal. 2005;35(4):222–227
  45. Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. Journal of Nuclear Medicine. 1994;35(10):1637–1644
  46. Herba MJ, Illescas FF, Thirlwell MP, Boos GJ, Rosenthall L, Atri M, et al. Hepatic malignancies: improved treatment with intraarterial Y-90. Radiology. 1988;169(2):311–314
  47. Anderson JH, Goldberg JA, Bessent RG, Kerr DJ, McKillop JH, Stewart I, et al. Glass yttrium-90 microspheres for patients with colorectal liver metastases. Radiotherapy Oncology. 1992;25(2):137–139
  48. Kennedy A, Coldwell D, Nutting C. Liver brachytherapy for unresectable colorectal metastases: US results 2000–2004. Abstract #145. 2005 GI cancer symposium. American Society of Clinical Oncology, 2005.
  49. Ho S, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. European Journal of Nuclear Medicine. 1997;24(3):293–298
  50. Fox RA, Klemp PF, Egan G, Mina LL, Burton MA, Gray BN. Dose distribution following selective internal radiation therapy. International Journal of Radiation Oncology Biology Physics. 1991;21(2):463–467
  51. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. Journal of Vascular and Interventional Radiology. 2005;16(2 Pt 1):205–213
  52. Rhee TK, Omary RA, Gates V, Mounajjed T, Larson AC, Barakat O, et al. The effect of catheter-directed CT angiography on yttrium-90radioembolization treatment of hepatocellular carcinoma. Journal of Vascular and Interventional Radiology. 2005;16(8):1085–1091
  53. Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. Journal of Vascular and Interventional Radiology. 2005;16(2 Pt 1):195–203
  54. Stubbs RS, Wickremesekera SK. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. Hepatobiliary. 2004;6(3):133–139
  55. Ariel IM, Pack GT. Treatment of inoperable cancer of the liver by intra-arterial radioactive isotopes and chemotherapy. Cancer. 1967;20(5):793–804
  56. Ariel IM, Padula G. Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. Journal of Surgical Oncology. 1978;10(4):327–336
  57. Grady ED. Internal radiation therapy of hepatic cancer. Diseases of the Colon & Rectum. 1979;22(6):371–375
  58. Ariel IM, Padula G. Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes. Journal of Surgical Oncology. 1982;20(3):151–156
  59. Blanchard RJ. Treatment of liver tumors with yttrium-90 microspheres. Canadian Journal of Surgery. 1983;26:442–443
  60. Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Canadian Association of Radiologists Journal. 1989;40(4):206–210
  61. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29(6):815–820
  62. Steel J, Baum A, Carr B. Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of cisplatin versus 90-yttrium microspheres (TheraSphere). Psycho-oncology. 2004;13:73–79
  63. Boan JF, Marti-Climont JM, Martinez A, Sangro B, Rodriguez J, Penuelas I, et al. Selective internal radiation therapy of primary or metastatic hepatic tumors with yttrium-90 microspheres. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31(Suppl 2):954
  64. Wong CY, Salem R, Qing F, Wong KT, Barker D, Gates V, et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. Journal of Nuclear Medicine. 2004;45(11):1892–1897
  65. Wong CY, Qing F, Savin M, Campbell J, Gates VL, Sherpa KM, et al. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging. Journal of Vascualar and Interventional Radiology. 2005;16(8):1101–1106
  66. Keng GH, Sundram FX, Yu SW, Somanesan S, Premaraj J, Oon CJ, et al. Preliminary experience in radionuclide therapy of hepatocellular carcinoma using hepatic intra-arterial radio-conjugates. Annals of the Academy of Medicine, Singapore. 2002;31(3):382–386

PII: S0960-7404(06)00004-1

doi: 10.1016/j.suronc.2006.01.003

Surgical Oncology
Volume 14, Issue 4 , Pages 179-193 , December 2005

Article Tools